Cisapride in the management of chronic functional dyspepsia: a multicenter, double-blind, placebo-controlled study

Clin Ther. 1987;10(1):44-51.


The effects of cisapride, a nondopaminolytic motility-enhancing agent, were studied in 56 patients with chronic functional dyspepsia; all had symptoms suggestive of delayed gastric emptying. The patients received 4 mg or 8 mg of cisapride or placebo orally three times daily for two successive three-week periods according to a randomized, double-blind, crossover study design. Although there was a high placebo response (55% showed good or excellent results), the global response to treatment was significantly (P = 0.024) in favor of cisapride (75% had good or excellent results). The drug was particularly superior to placebo (P = 0.03) in the improvement of a cluster of symptoms typical of postprandial discomfort, including early satiety and nausea. Side effects were minimal.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Chronic Disease
  • Cisapride
  • Clinical Trials as Topic
  • Double-Blind Method
  • Drug Administration Schedule
  • Dyspepsia / drug therapy*
  • Female
  • Gastric Emptying / drug effects
  • Humans
  • Male
  • Middle Aged
  • Piperidines / administration & dosage
  • Piperidines / adverse effects
  • Piperidines / therapeutic use*
  • Random Allocation


  • Piperidines
  • Cisapride